Studio a dose singola ascendente dell'iniezione HEC-151
Uno Studio di Fase I che Valuta la Sicurezza, la Tollerabilità, le Caratteristiche Farmacocinetiche/Farmacodinamiche di una Singola Dose di Iniezione HEC-151 in Partecipanti Cinesi Sani in uno Studio Monocentrico, Randomizzato, Controllo Placebo (a Singolo Cieco) e Controllo Positivo (a Aperto)
Evaluate the safety, tolerability, PK/PD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Chengyong Tang, Doctor
- Numero di telefono: +8618983286980
- Email: 17235387@qq.com
Luoghi di studio
-
-
Bishan
-
Chongqing, Bishan, Cina, 402760
- Reclutamento
- No. 9, Shuangxing Avenue,, Bishan
-
Contatto:
- Chengyong Tang, Doctor
- Numero di telefono: 8618983286980
- Email: 17235387@qq.com
-
-
Chongqing Municipality
-
Bishan, Chongqing Municipality, Cina, 402760
- Non ancora reclutamento
- No. 9, Shuangxing Avenue,
-
Contatto:
- Chengyong Tang, Doctor
- Numero di telefono: +8618983286980
- Email: 17235387@qq.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Voluntarily participate in the trial and sign the informed consent form, understanding and abiding by the research procedures;
- When signing the informed consent form, men aged 18-45 years old (including the boundary value) are eligible;
- During the screening process, male subjects with a body weight of ≥ 50 kg and a body mass index (BMI) of ≥ 19.0 and ≤ 24.0 kg/m2 are included;
- Normal glucose tolerance [3.9 mmol/L < fasting blood glucose (FPG) < 6.1 mmol/L, and 2-hour post-glucose tolerance test (OGTT) blood glucose after sugar intake < 7.8 mmol/L];
- Normal results of insulin release test (IRT), or abnormal results but judged by the researcher to have no clinical significance;
- Glycated hemoglobin (HbA1c) < 5.7%;
- During the study period, there are no plans for reproduction, sperm collection, or sperm donation, and are willing to take effective contraceptive measures throughout the study period until 3 months after the administration of the investigational drug.
Exclusion Criteria:
- Participants with abnormal medical histories or surgical histories judged clinically significant by the researchers, or currently suffering from any diseases in the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, etc. that are judged clinically significant by the researchers, or any other diseases or physiological conditions that can significantly affect the absorption, distribution, metabolism or excretion of the drugs;
- Participants who have a known severe allergic history or are allergic to the test drugs and any of their components;
- Participants who had severe trauma or undergone surgery within 90 days before the screening, or plan to undergo major surgery during the study;
- Participants who have a history of hypoglycemia or hyperglycemia within 90 days before the screening, or have a family history of diabetes (first-degree direct relatives);
- Participants who have donated blood or suffered significant blood loss (≥ 400 mL) within 90 days before the screening, or plan to donate blood during the study;
- Participants who have acute diseases or concurrent medication use from the signing of the informed consent form to the first administration of the drug;
- Participants whose vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray examination, etc. results are abnormal and judged by the researchers to have clinical significance;
- Participants whose test results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), combined human immunodeficiency virus antigen antibody (HIV), or syphilis spirochete antibody (TP) are positive;
- Participants who have a history of drug abuse or drug use, or whose urine drug screening is positive before the screening;
- Participants who have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, health supplements (except for regular supplementary vitamins and calcium) within 30 days before the screening;
- Participants who have participated in any clinical research of drugs or devices (defined as receiving the test drugs or devices) within 90 days before the screening;
- Participants who have received any vaccine within 30 days before the screening, or plan to receive any type of vaccine during the study;
- Participants who smoke more than 5 cigarettes per day within 90 days before the screening, or cannot comply with the smoking prohibition rule during the study;
- Participants who frequently drink alcohol, that is, consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine), or have a positive alcohol breath test; or who cannot comply with the alcohol prohibition rule during the study;
- Participants who consume excessive tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 mL) or food (such as chocolate) every day within 90 days before the screening, or during the study;
- Participants who have used special diets (including dragon fruit, mango, pomelo, etc.) and/or xanthine diet (salmon, sardines, liver, kidney, etc.) or have other factors affecting drug absorption, distribution, metabolism, and excretion before the signing of the informed consent form to the use of the test drugs, or who cannot comply with the prohibition of eating during the study;
- Participants who have had significant changes in diet or exercise habits within 90 days before the screening, or have engaged in intense exercise before the signing of the informed consent form to the use of the test drugs, or cannot stop during the study;
- Participants who have difficulty in venous blood collection, or cannot tolerate venipuncture, or have a history of fainting or hematemesis;
- Participants who, in the researcher's opinion, have other factors that are not suitable for participating in this study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: HEC-151 Injection
The participants received an abdominal subcutaneous HEC-151 Injection in the morning of Day 1. |
Subcutaneous injection in the abdominal area |
|
Comparatore attivo: Insulin Degludec
The participants received an abdominal subcutaneous injection of Insulin Degludec in the morning of Day 1. |
Subcutaneous injection in the abdominal area |
|
Comparatore placebo: Placebo
The participants received an abdominal subcutaneous Injection of placebo in the morning of Day 1. |
Subcutaneous injection in the abdominal area |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Adverse event
Lasso di tempo: From Day1 to Day36
|
Frequency, type and severity of adverse events/serious adverse events. |
From Day1 to Day36
|
|
Electrocardiogram parameter(Heart rate)
Lasso di tempo: From Day1 to Day36
|
Evaluation the heart rate of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Electrocardiogram parameter(PR interval)
Lasso di tempo: From Day1 to Day36
|
Evaluation the PR interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Electrocardiogram parameter(QTcF interval)
Lasso di tempo: From Day1 to Day36
|
Evaluation the QTcF interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Electrocardiogram parameter(QRS interval)
Lasso di tempo: From Day1 to Day36
|
Evaluation the QRS interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Body temperature)
Lasso di tempo: From Day1 to Day36
|
Evaluation the body temperature of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Blood pressure)
Lasso di tempo: From Day1 to Day36
|
Evaluation the blood pressure of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Pulse)
Lasso di tempo: From Day1 to Day36
|
Evaluation the pulse of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Respiration)
Lasso di tempo: From Day1 to Day36
|
Evaluation the respiration of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cmax
Lasso di tempo: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
AUC0-t
Lasso di tempo: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
Tmax
Lasso di tempo: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
T1/2
Lasso di tempo: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
CL/F
Lasso di tempo: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
GIRmax
Lasso di tempo: From Day1 to Day36
|
Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
tGIRmax
Lasso di tempo: From Day1 to Day36
|
Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
AUCGIR
Lasso di tempo: From Day1 to Day36
|
Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
ADA(Anti-Drug Antibody)
Lasso di tempo: From Day1 to Day36
|
Evaluate the Immunogenic characteristics of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- HEC-151-DM-101
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .